Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
MAZE
MAZE
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
MAZE News
Biotech Landscape Update: Regulatory Approvals and Mergers
Mar 27 2026
NASDAQ.COM
Investigation into Potential Claims for Maze Therapeutics Investors
Mar 26 2026
Globenewswire
Maze Therapeutics Executive Exercises Stock Options Amid Market Volatility
Mar 25 2026
Fool
Maze Therapeutics Shares Plunge 37% Despite Positive Trial Data
Mar 25 2026
seekingalpha
Maze Therapeutics Reports Positive Phase 2 Data for MZE829 in Kidney Disease
Mar 25 2026
NASDAQ.COM
Maze Therapeutics Q4 Earnings Beat Expectations
Mar 25 2026
seekingalpha
Maze Therapeutics Inc Reports Q4 Pretax Loss of $34.568 Million, Slightly Better than IBES Estimate of $34.7 Million
Mar 25 2026
moomoo
Maze Therapeutics Inc Reports Q4 Operating Loss of $38.059 Million, Exceeding IBES Estimate of $36 Million
Mar 25 2026
moomoo
Maze Therapeutics Executive Sells Shares for $1.51 Million
Mar 22 2026
NASDAQ.COM
Maze Therapeutics Executive Stock Transaction Report
Mar 22 2026
Fool
Maze Therapeutics Executive Sells All Shares Ahead of Q4 Earnings Report
Mar 22 2026
Yahoo Finance
Wall Street Analysts Adjust Ratings on Key Stocks
Mar 10 2026
Benzinga
Chronic Kidney Disease Market Growth Drivers
Mar 03 2026
Newsfilter
a16z Capital Management Acquires Navan Shares
Feb 18 2026
Fool
a16z Capital Management Acquires Navan Shares
Feb 18 2026
NASDAQ.COM
Maze Therapeutics Executive Sells Stock Options
Feb 16 2026
Fool
Show More News
